RPG Life Sciences Limited — Updates, 02-09-2026: General Updates
02-09-2026 | 10:19 pm
02-09-2026 | 10:19 pm
RPG Life Sciences' subsidiary approved acquiring Raghava Life Sciences' API & intermediates business as a slump sale for up to 135 Cr. This expands RPG's API footprint, adding manufacturing, R&D, and 29 molecules. The acquired business generated 19 Cr revenue in FY26.
No comments yet. Be the first to comment!
